Abstract
Hyperhomocysteinemia (HHcy) has been associated with cognitive impairment in various neurological diseases. Cognitive impairment occurs early in multiple sclerosis (MS). Conflicting data have been reported regarding plasma total homocysteine (tHcy) levels in MS patients, and the impact of HHcy on cognitive impairment in MS is not known. This study investigated whether plasma total homocysteine levels are increased in MS and if HHcy is associated with cognitive impairment in MS. We compared tHcy levels in 94 patients with MS and 53 healthy age-matched controls. We used a neuropsychological test battery that included the Raven’s Coloured Progressive Matrices, the Visual Search Test, the Trail Making Test A and B, the Immediate and Delayed Recall of a Short Story, the 30 Paired Word Associates, the Rey-Osterrieth Complex Figure Test, and the Semantic and Verbal Fluency Tests. Clinical (sex, age, type of MS, relapse, disease duration, coexisting disease, smoking habit, and physical disability) and laboratory variables (HHcy, low serum levels of folate and vit.B12, MTHFR genotype) were evaluated for their ability to predict cognitive impairment. The mean tHcy was higher in patients (13.19 μmol/L, SD5.58) than in controls (9.81 μmol/L, SD2.53; p < 0.001). Univariate analysis determined the following factors to be associated with cognitive impairment: higher age at observation, chronic progressive course of disease, longer disease duration,moderate or severe physical disability, and frequency of HHcy. With multivariate regression analysis, there remained a significant association only between frequency of HHcy and cognitive impairment (β 0.262, p = 0.01). We conclude that tHcy levels are increased in MS and that HHcy is associated with cognitive impairment in this disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis. A reappraisal after 10 years. Arch Neurol 58:1602–1606
Piras MR, Magnano I, Canu ED, Paulus KS, Satta WM, Soddu A, Conti M, Achee A, Solinas G, Aiello I (2003) Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings. J Neurol Neurosurg Psychiatry 74:878–885
Kujala P, Portin R, Ruutiainen J (1997) The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 120:289–297
Rovaris M, Filippi M, Falautano M, Minicucci L, Rocca MA, Martinelli V, Comi G (1998) Relation between MR abnormalies and patterns of cognitive impairment in multiple sclerosis. Neurology 6:1601–1608
Selhub J, Miller JW (1992)The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131–138
Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19:217–246
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346:476–483
Diaz-Arrastia R (2000) Homocysteine and Neurologic Disease. Arch Neurol 57:1422–1427
Dufouil C, Alperovitch A, Ducros V, Tzourio C (2003) Homocysteine, White Matter Hyperintensities, and Cognition in Healthy Elderly People. Ann Neurol 53:214–221
Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, Breteler MM (2002) Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59:1375–1380
Rio J, Montalban J, Tintore M, Codina A, Malinow MR (1994) Serum homocysteine levels in multiple sclerosis. Arch Neurol 51:1181
Vrethem M, Mattsson E, Hebelka H, Leerbeck K, Osterberg A, Landtblom AM, Balla B, Nilsson H, Hultgren M, Brattstrom L, Kagedal B (2003) Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 9:239–245
Ramsaransing GSM, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De Keyser J (2006) Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry 77:189–192
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for Multiple Sclerosis: 2005 Revisions to the “Mc- Donald Criteria”. Ann Neurol 58:840–846
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Basso A, Capitani E, Laiacona M (1987) Raven's coloured progressive matrices: normative values on 305 adult normal controls. Funct Neurol 2:189–194
Spinnler H, Tognoni G (1987) Gruppo Italiano per lo Studio Neuropsicologico dell’Invecchiamento: Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci (Suppl 8):6
Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17:305–309
Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G, Cappa S (1986) Tre test clinici di memoria verbale a lungo termine. Taratura su soggetti normali. Arch Psicol Neurol Psichiatr 47:278–296
Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 22:443–447
Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G, Cappa S (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Arch Psicol Neurol Psichiatr 47:477–506
Frantzen F, Faaren AL, Alfheim I, Nordheim AK (1998) Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 44:311–316
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet 10:111–113
Feng L, Ng TP, Chuah L, Niti M, Kua EH (2006) Homocysteine, folate, and vitamin B-12 and cognitive performance in older Chinese adults: findings from the Singapore Longitudinal Ageing Study. Am J Clin Nutr 84:1506–1512
Teunissen CE, van Boxtel MP, Jolles J, de Vente J, Vreeling F, Verhey F, Polman CH, Dijkstra CD, Blom HJ (2005) Homocysteine in relation to cognitive performance in pathological and nonpathological conditions. Clin Chem Lab Med 43:1089–1095
Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, Farina D, Fazio MC, Girlanda P, Le Pira F, Liguori M, Lugaresi A, Nocentini U, Reggio A, Salemi G, Tedeschi G, Trojano M, Valentino P, Quattrone A (2004) Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 251:1208–1214
Calabrese P (2006) Neuropsychology of multiple sclerosis. An overview. J Neurol 253 (Suppl 1):10–15
Amato MP, Zipoli V, Portaccio E (2006) Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 245:41–46
den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM (2003) Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126:170–175
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russo, C., Morabito, F., Luise, F. et al. Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol 255, 64–69 (2008). https://doi.org/10.1007/s00415-007-0668-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-007-0668-7